XT
NKTR icon

XTX Topco’s Nektar Therapeutics NKTR Stock Holding History

XTX Topco’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$295K Sell
4,103
-3,093
-43% -$176K 0.01% 2492
2025
Q4 		$304K Buy
7,196
+1,299
+22% +$72.7K 0.01% 2050
2025
Q3 		$336K Buy
+5,897
New +$195K 0.02% 1422
2025
Q2 		– Sell
-3,828
Closed -$39K – 2904
2025
Q1 		$39K Sell
3,828
-12,485
-77% -$163K ﹤0.01% 2032
2024
Q4 		$228K Buy
16,313
+13,968
+596% +$246K 0.02% 1452
2024
Q3 		$45.7K Buy
+2,345
New +$44.7K ﹤0.01% 1705
2024
Q1 		– Sell
-4,881
Closed -$41.4K – 2157
2023
Q4 		$41.4K Buy
+4,881
New +$37K 0.01% 1263
2023
Q3 		– Sell
-788
Closed -$6.8K – 1859
2023
Q2 		$6.8K Buy
+788
New +$8.4K ﹤0.01% 1350
2023
Q1 		– Sell
-10,910
Closed -$370K – 1534
2022
Q4 		$370K Buy
10,910
+8,284
+315% +$401K 0.08% 446
2022
Q3 		$126K Buy
2,626
+615
+31% +$36.6K 0.03% 899
2022
Q2 		$115K Sell
2,011
-254
-11% -$16K 0.05% 611
2022
Q1 		$183K Buy
+2,265
New +$335K 0.08% 429

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

XTX Topco's NKTR Position: Q1 2026 in Review

XTX Topco reduced its Nektar Therapeutics (NKTR) stake by 43% in Q1 2026, selling an estimated $176K and leaving 4,103 shares worth $295K. The position accounts for 0.01% of the portfolio, ranked #2492.

XTX Topco first reported a position in NKTR in Q1 2022 and has held it in 12 quarters since. The position peaked at $370K in Q4 2022. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • XTX Topco held 4,103 shares of Nektar Therapeutics worth $295K as of Q1 2026.
  • XTX Topco sold 3,093 Nektar Therapeutics shares in Q1 2026, an estimated $176K.
  • Nektar Therapeutics made up 0.01% of XTX Topco's portfolio in Q1 2026, its #2492 holding.
  • XTX Topco first reported a position in Nektar Therapeutics in Q1 2022 and has held it in 12 quarters since.
  • XTX Topco's Nektar Therapeutics position peaked at $370K in Q4 2022.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.